Trials / Recruiting
RecruitingNCT06091748
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
An Open-label, Single Arm Clinical Trial of Gallium (68Ga) Edotreotide PET-CT Scan for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-DOTATOC | Detection of somatostatin positive lesions in GEP-NETs |
Timeline
- Start date
- 2024-02-22
- Primary completion
- 2025-11-01
- Completion
- 2025-11-01
- First posted
- 2023-10-19
- Last updated
- 2025-06-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06091748. Inclusion in this directory is not an endorsement.